Scarica l'app Stockscreener
1.48
1.33%
-0.02
Dopo l'orario di chiusura:
1.51
0.03
+2.03%
Precedente Chiudi:
$1.50
Aprire:
$1.49
Volume 24 ore:
158.93K
Relative Volume:
0.53
Capitalizzazione di mercato:
$177.91M
Reddito:
-
Utile/perdita netta:
$-13.73M
Rapporto P/E:
-11.38
EPS:
-0.13
Flusso di cassa netto:
$-3.92M
1 W Prestazione:
-0.67%
1M Prestazione:
-11.38%
6M Prestazione:
-0.67%
1 anno Prestazione:
+101.09%
Intervallo 1D:
$1.47
$1.56
Intervallo di 1 settimana:
$1.44
$1.61
Portata 52W:
$0.6302
$2.60
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
Nome
Tiziana Life Sciences Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Confronta TLSA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TLSA
Tiziana Life Sciences Ltd
|
1.48 | 180.31M | 0 | -13.73M | -3.92M | -0.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-12-22 | Iniziato | B. Riley Securities | Buy |
| 2018-12-17 | Iniziato | Laidlaw | Buy |
Tiziana Life Sciences Ltd Borsa (TLSA) Ultime notizie
Tiziana Life Sciences (NASDAQ:TLSA) Trading Up 7.4% – Still a Buy? - Defense World
Tiziana Life Sciences (NASDAQ:TLSA) Trading Up 7.4%Still a Buy? - MarketBeat
Tiziana Life Sciences Files Annual Safety Report for Intranasal Foralumab with FDA - MarketScreener
Tiziana Life Sciences files annual safety report for intranasal foralumab - Yahoo Finance
Is Tiziana Life Sciences Ltd a good long term investmentSupport and Resistance Levels & Free Risk Assessment and Control - earlytimes.in
Tiziana Life Sciences submits annual safety report for intranasal foralumab to FDA - Proactive financial news
Tiziana Life Sciences Reports Positive Safety Profile for Intranasal Foralumab Following 37.4 Patient-Years of Exposure - Quiver Quantitative
Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA - The Manila Times
Small cap wrap: Tiziana Life Sciences, 374Water, First Phosphate... - Proactive financial news
Operating expenses (excl. COGS) of Tiziana Life Sciences Ltd. – GETTEX:0RP - TradingView — Track All Markets
Tiziana Life Sciences begins dosing in Phase 2 Alzheimer’s trialICYMI - Proactive financial news
Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman - The Manila Times
Tiziana Life Sciences Chair Boosts Stake to 36% with December Share Purchase - TipRanks
How buybacks impact Tiziana Life Sciences Ltd stock valueRecession Risk & Reliable Breakout Stock Forecasts - Улправда
Tiziana Life Sciences chairman increases stake to over 36% By Investing.com - Investing.com South Africa
Tiziana Life Sciences (TLSA) Chairman Expands Stake in the Compa - GuruFocus
Tiziana Life Sciences executive chairman increases stake - Proactive financial news
Why Tiziana Life Sciences Ltd stock is considered a top pickWeekly Stock Summary & Daily Risk Controlled Trade Plans - Bölüm Sonu Canavarı
Tiziana Life Sciences Executive Chairman Gabriele Cerrone Acquires Additional Shares, Increasing Ownership to 36.08% - Quiver Quantitative
Tiziana Life Sciences chairman increases stake to over 36% - Investing.com
Biotech founder lifts personal stake to 36% with latest share buy - Stock Titan
Can Tiziana Life Sciences Ltd stock maintain operating marginsShort Setup & Free Weekly Chart Analysis and Trade Guides - Улправда
Is Tiziana Life Sciences Ltd stock a buy on dipsIPO Watch & Safe Entry Zone Tips - DonanımHaber
Is Tiziana Life Sciences Ltd stock gaining market share2025 Market Overview & Daily Volume Surge Signals - Улправда
What risks investors should watch in Tiziana Life Sciences Ltd stockJuly 2025 Setups & Free Low Drawdown Momentum Trade Ideas - Улправда
How Tiziana Life Sciences Ltd stock performs during Fed tightening cyclesJuly 2025 Intraday Action & Stepwise Swing Trade Plans - Улправда
Tiziana Life Sciences Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Small cap wrap: Tiziana Life Sciences, NanoViricides, 1911 Gold, Protalix BioTherapeutics… - Proactive Investors
Tiziana Life Sciences doses first patient in Phase 2 Alzheimer’s clinical trial - Proactive financial news
Tiziana Life Sciences (NASDAQ: TLSA) marks Nasdaq bell with foralumab - Stock Titan
Tiziana Life Sciences to Ring the Closing Bell at Nasdaq - The Manila Times
Biotech behind nasal antibody for Alzheimer's to ring Nasdaq bell - Stock Titan
Tiziana Life Sciences doses first patient in Phase 2 Alzheimer's clinical trial - MarketScreener
TLSA Initiates Phase 2 Trial of Intranasal Foralumab for Alzheimer's Patients - GuruFocus
Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial - The Manila Times
Tiziana Life Sciences doses first patient in mid-stage Alzheimer’s trial - Proactive Investors
Tiziana Life Sciences Doses First Patient with Intranasal Foralumab in Phase 2 Alzheimer’s Disease Trial - Quiver Quantitative
Tiziana Life Sciences (TLSA) begins Phase 2 intranasal foralumab AD trial - Stock Titan
New intranasal antibody trial targets neuroinflammation in early Alzheimer’s - Stock Titan
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer - The Manila Times
Tiziana Life Sciences CEO purchases 163,400 shares in open market By Investing.com - Investing.com Canada
Tiziana Life Sciences (TLSA) CEO boosts stake with 163,400-share purchase - Stock Titan
TLSA CEO Bolsters Stake with New Share Acquisition - GuruFocus
Tiziana Life Sciences CEO Increases Stake With Share Purchase - marketscreener.com
Tiziana Life Sciences CEO purchases 163,400 shares in open market - Investing.com
Ivor Elrifi Acquires Additional Shares of Tiziana Life Sciences Amidst Ongoing Clinical Development of Foralumab - Quiver Quantitative
Tiziana (NASDAQ: TLSA) CEO buys 163,400 shares in open market, now 357,848 - Stock Titan
Tiziana Life Sciences withdraws proposed public offering due to market conditions - Investing.com Nigeria
Tiziana Life Sciences withdraws proposed share offering - Proactive Investors
Tiziana CEO boosts stake with open-market share purchase - Proactive financial news
Tiziana Life Sciences Rescinds Proposed Public Offering - Nasdaq
Tiziana Life Sciences Ltd Azioni (TLSA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):